DK3085363T3 - Lægemiddelindgivelsesindretning til at tilvejebringe lokalanalgesi, lokalanæstesi eller nerveblokade - Google Patents
Lægemiddelindgivelsesindretning til at tilvejebringe lokalanalgesi, lokalanæstesi eller nerveblokade Download PDFInfo
- Publication number
- DK3085363T3 DK3085363T3 DK16154811.0T DK16154811T DK3085363T3 DK 3085363 T3 DK3085363 T3 DK 3085363T3 DK 16154811 T DK16154811 T DK 16154811T DK 3085363 T3 DK3085363 T3 DK 3085363T3
- Authority
- DK
- Denmark
- Prior art keywords
- bupivacaine
- local anesthesia
- drug
- collagen
- analgesia
- Prior art date
Links
- 238000002690 local anesthesia Methods 0.000 title claims description 38
- 238000004458 analytical method Methods 0.000 title description 4
- 206010029216 Nervousness Diseases 0.000 title description 2
- 238000001356 surgical procedure Methods 0.000 claims description 46
- 230000036592 analgesia Effects 0.000 claims description 45
- 238000012377 drug delivery Methods 0.000 claims description 43
- 102000008186 Collagen Human genes 0.000 claims description 39
- 108010035532 Collagen Proteins 0.000 claims description 39
- 229920001436 collagen Polymers 0.000 claims description 39
- 239000000515 collagen sponge Substances 0.000 claims description 33
- 210000005036 nerve Anatomy 0.000 claims description 29
- 239000011159 matrix material Substances 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 21
- 229960001050 bupivacaine hydrochloride Drugs 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 20
- JCQBWMAWTUBARI-UHFFFAOYSA-N tert-butyl 3-ethenylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C=C)C1 JCQBWMAWTUBARI-UHFFFAOYSA-N 0.000 claims description 20
- 206010002091 Anaesthesia Diseases 0.000 claims description 16
- 230000037005 anaesthesia Effects 0.000 claims description 16
- 102000013373 fibrillar collagen Human genes 0.000 claims description 16
- 108060002894 fibrillar collagen Proteins 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 230000003187 abdominal effect Effects 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 13
- 230000009885 systemic effect Effects 0.000 claims description 12
- 238000011538 abdominal hysterectomy Methods 0.000 claims description 10
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 claims description 8
- 210000000115 thoracic cavity Anatomy 0.000 claims description 7
- 231100000419 toxicity Toxicity 0.000 claims description 5
- 230000001988 toxicity Effects 0.000 claims description 5
- 238000002350 laparotomy Methods 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- 230000000399 orthopedic effect Effects 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 62
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 59
- 229960003150 bupivacaine Drugs 0.000 description 59
- 208000002193 Pain Diseases 0.000 description 47
- 230000036407 pain Effects 0.000 description 45
- 229940088679 drug related substance Drugs 0.000 description 39
- 238000000034 method Methods 0.000 description 38
- 239000008186 active pharmaceutical agent Substances 0.000 description 34
- 229960005181 morphine Drugs 0.000 description 31
- 229940035674 anesthetics Drugs 0.000 description 24
- 239000003193 general anesthetic agent Substances 0.000 description 24
- 208000004550 Postoperative Pain Diseases 0.000 description 22
- 238000009802 hysterectomy Methods 0.000 description 20
- 230000008595 infiltration Effects 0.000 description 19
- 238000001764 infiltration Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 18
- 102000012422 Collagen Type I Human genes 0.000 description 15
- 108010022452 Collagen Type I Proteins 0.000 description 15
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 15
- 206010052428 Wound Diseases 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 15
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 15
- 230000003444 anaesthetic effect Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- -1 amino ester Chemical class 0.000 description 12
- 230000001954 sterilising effect Effects 0.000 description 12
- 238000004659 sterilization and disinfection Methods 0.000 description 12
- 241000283690 Bos taurus Species 0.000 description 10
- 230000002980 postoperative effect Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 238000007726 management method Methods 0.000 description 8
- 238000012552 review Methods 0.000 description 8
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 7
- 239000007943 implant Substances 0.000 description 7
- 229960004194 lidocaine Drugs 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 210000002435 tendon Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001949 anaesthesia Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 5
- 238000007429 general method Methods 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 229960004288 levobupivacaine Drugs 0.000 description 5
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 5
- 239000003589 local anesthetic agent Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 4
- 210000003815 abdominal wall Anatomy 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 238000011970 concomitant therapy Methods 0.000 description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 4
- 229960001259 diclofenac Drugs 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 229960002409 mepivacaine Drugs 0.000 description 4
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 4
- 230000003533 narcotic effect Effects 0.000 description 4
- 210000004303 peritoneum Anatomy 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 229960001549 ropivacaine Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical class NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 241001602876 Nata Species 0.000 description 3
- 102000057297 Pepsin A Human genes 0.000 description 3
- 108090000284 Pepsin A Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 208000002847 Surgical Wound Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 238000012084 abdominal surgery Methods 0.000 description 3
- 210000001361 achilles tendon Anatomy 0.000 description 3
- 229960003831 articaine Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940013767 bupivacaine injection Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229920001684 low density polyethylene Polymers 0.000 description 3
- 239000004702 low-density polyethylene Substances 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 229940111202 pepsin Drugs 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 229960001807 prilocaine Drugs 0.000 description 3
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000011539 total abdominal hysterectomy Methods 0.000 description 3
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 3
- 229950002569 trimecaine Drugs 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- 241001535291 Analges Species 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010038678 Respiratory depression Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000012382 advanced drug delivery Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229940052294 amide local anesthetics Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 210000003195 fascia Anatomy 0.000 description 2
- 238000005429 filling process Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 238000012792 lyophilization process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 210000000505 parietal peritoneum Anatomy 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 229940127558 rescue medication Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 description 1
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000023661 Haematological disease Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
- 208000011768 Leiomyosarcoma of the cervix uteri Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 238000007486 appendectomy Methods 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000022371 chronic pain syndrome Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000011902 gastrointestinal surgery Methods 0.000 description 1
- 235000015201 grapefruit juice Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229960003029 ketobemidone Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940052264 other local anesthetics in atc Drugs 0.000 description 1
- 125000000963 oxybis(methylene) group Chemical group [H]C([H])(*)OC([H])([H])* 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Lægemiddelindgivelsesindretning egnet til at tilvejebringe lokalanalgesi, lokalanæstesi eller nerveblokade på et sted i et menneske eller dyr med behov derfor, idet indretningen omfatter en fibrillær kollagenmatrix; og mindst et lægemiddel, idet det mindst ene lægemiddel er i alt væsentligt homogent dispergeret i kollagenmatricen, hvor lægemiddelindgivelsesindretningen omfatter en eller flere frysetørrede kollagensvampe, som indeholder i alt 250 mg eller 200 mg af vandfri bupivacain-hydroklorid.
2. Lægemiddelindgivelsesindretning ifølge krav 1, hvor, når mennesket eller dyret har behov for lokalanalgesi, lokalanæstesi eller nerveblokade efter gastrointestinal (GI) kirurgi, da omfatter lægemiddelindgivelsesindretningen en flerhed af svampe, som indeholder i alt 200 mg bupivacain-hydroklorid, hvor svampene har et overfladeareal på 100 cm2 og en dybde eller tykkelse på 0,5 cm.
3. Indretning ifølge kravene 1-2, hvor analgesi tilvejebringes uden bivirkninger associeret med toksicitet fra lægemiddelindgivelsesindretningen.
4. Indretning ifølge kravene 1-3, hvor indretningen reducerer patientens behovfor systemisk analgesi.
5. Anvendelse afen lægemiddelindgivelsesindretning omfattende en fibrillær kollagenmatrix; og mindst et lægemiddel, idet det mindst ene lægemiddel er i alt væsentligt homogent dispergeret i kollagenmatrixen til fremstillingen af et medikament til at tilvejebringe lokalanalgesi, lokalanæstesi eller nerveblokade i mennesket eller dyret med behov derfor, idet analgesien, anæstesien eller nerveblokaden omfatter at indgive medikamentet på stedet i et menneske eller dyr med behov derfor, hvor lægemiddelindgivelsesindretningen omfatter en eller flere frysetørrede kollagensvampe, som indeholder i alt 250 mg eller 200 mg af vandfri bupivacain-hydroklorid.
6. Anvendelse ifølge krav 5, hvor mindst en svamp placeres tilstødende det kirurgiske sted, mindst en svamp placeres på tværs af indsnittet i væggen af kropshulrummet og mindst en svamp placeres mellem hinden og huden rundt om indsnittet.
7. Anvendelse ifølge krav 6, hvor anvendelsen er til at tilvejebringe lokalanalgesi, lokalanæstesi eller nerveblokade i et menneske efter en laparotomi.
8. Anvendelse ifølge kravene 6-7, hvor anvendelsen er til at tilvejebringe lokalanalgesi, lokalanæstesi eller nerveblokade i et menneske efter ortopædisk, abdominal, gynækologisk eller torakale kirurgiske procedurer.
9. Anvendelse ifølge krav 8, hvor anvendelsen er til at tilvejebringe lokalanalgesi, lokalanæstesi eller nerveblokade i et menneske efter godartet abdominale eller torakale kirurgiske procedurer.
10. Anvendelse ifølge krav 9, hvor anvendelsen er til at tilvejebringe lokalanalgesi, lokalanæstesi eller nerveblokade i et menneske efter abdominale hysterektomier, myomektomi og adneks kirurgi.
11. Indretning ifølge kravene 1-4 eller anvendelsen ifølge kravene 5-10, hvor svampene har en dybde på 0,5 cm.
12. Indretning ifølge kravene 1-4 eller anvendelsen ifølge kravene 5-10, hvor hver svamp har en længde på 5 cm og bredde på 5 cm.
13. Anvendelse ifølge kravene 5-10, hvor analgesi tilvejebringes uden bivirkninger associeret med toksicitet fra lægemiddelindgivelsesindretningen.
14. Anvendelse ifølge kravene 5-10, hvor indretningen reducerer patientens behov for systemisk analgesi.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE2007/0220A IE85880B1 (en) | 2007-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
| US11/692,337 US20080241243A1 (en) | 2007-03-28 | 2007-03-28 | Drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
| EP08719893.3A EP2139457B1 (en) | 2007-03-28 | 2008-03-28 | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3085363T3 true DK3085363T3 (da) | 2019-04-29 |
Family
ID=39540798
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08719893.3T DK2139457T3 (da) | 2007-03-28 | 2008-03-28 | Lægemiddelafgivelsesindretning til at tilvejebringe lokal analgesi, lokal anæstesi eller nerveblokade |
| DK16154811.0T DK3085363T3 (da) | 2007-03-28 | 2008-03-28 | Lægemiddelindgivelsesindretning til at tilvejebringe lokalanalgesi, lokalanæstesi eller nerveblokade |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08719893.3T DK2139457T3 (da) | 2007-03-28 | 2008-03-28 | Lægemiddelafgivelsesindretning til at tilvejebringe lokal analgesi, lokal anæstesi eller nerveblokade |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP2139457B1 (da) |
| JP (1) | JP5372905B2 (da) |
| CY (2) | CY1117814T1 (da) |
| DE (1) | DE202008018583U1 (da) |
| DK (2) | DK2139457T3 (da) |
| ES (2) | ES2718542T3 (da) |
| HR (2) | HRP20160743T1 (da) |
| HU (2) | HUE043185T2 (da) |
| IE (1) | IES20080229A2 (da) |
| LT (1) | LT3085363T (da) |
| PL (2) | PL3085363T3 (da) |
| PT (2) | PT3085363T (da) |
| SI (2) | SI2139457T1 (da) |
| TR (1) | TR201905174T4 (da) |
| WO (1) | WO2008117268A2 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47826E1 (en) | 2007-03-28 | 2020-01-28 | Innocoll Pharmaceuticals Limited | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage |
| JP2012507383A (ja) * | 2008-11-06 | 2012-03-29 | イノコル テクノロジーズ リミティッド | 薬剤送達インプラントおよびその作製のためのプロセス |
| US8858983B2 (en) | 2009-04-30 | 2014-10-14 | Medtronic, Inc. | Antioxidants and antimicrobial accessories including antioxidants |
| US8911427B2 (en) | 2010-12-28 | 2014-12-16 | Medtronic, Inc. | Therapeutic agent reservoir delivery system |
| US9205150B2 (en) * | 2011-12-05 | 2015-12-08 | Incept, Llc | Medical organogel processes and compositions |
| SMT202100257T1 (it) * | 2012-01-09 | 2021-07-12 | Innocoll Pharm Ltd | Un collagene modificato |
| US10220093B2 (en) | 2013-02-28 | 2019-03-05 | Mira Pharma Corporation | Long-acting semi-solid lipid formulations |
| AU2014223993B2 (en) * | 2013-02-28 | 2016-09-08 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid formulations and its compostions |
| RU2561301C1 (ru) * | 2014-10-06 | 2015-08-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Омский государственный аграрный университет имени П.А. Столыпина" | Способ трансфеморальной блокады нервов мочевого пузыря у мелких животных |
| US10561606B2 (en) | 2017-12-06 | 2020-02-18 | Mira Pharma Corporation | Injectable long-acting local anesthetic semi-solid gel formulations |
| US11426418B2 (en) | 2017-12-06 | 2022-08-30 | Mira Pharma Corporation | Injectable long-acting semi-solid gel formulations |
| AU2022213016A1 (en) * | 2021-02-01 | 2023-08-24 | Massey University | Post-operative pain management |
| WO2022219179A1 (en) * | 2021-04-15 | 2022-10-20 | Innocoll Pharmaceuticals Limited | Drug-release implant for soft tissue surgery |
| EP4376806A2 (en) * | 2021-07-28 | 2024-06-05 | Innocoll Pharmaceuticals Limited | Bupivacaine-collagen drug delivery implant and methods of making and using thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4125400C2 (de) * | 1991-07-31 | 2000-08-17 | Edwin Klaus | Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen |
| JPH08143449A (ja) * | 1994-11-17 | 1996-06-04 | Lederle Japan Ltd | 徐放性局所麻酔用注射剤 |
| US7119062B1 (en) * | 2001-02-23 | 2006-10-10 | Neucoll, Inc. | Methods and compositions for improved articular surgery using collagen |
| WO2006002365A2 (en) * | 2004-06-24 | 2006-01-05 | Angiotech International Ag | Microparticles with high loadings of a bioactive agent |
| BRPI0515372B8 (pt) * | 2004-09-17 | 2021-05-25 | Durect Corp | composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico |
| CA2580357C (en) * | 2004-09-30 | 2014-01-28 | Covalon Technologies Inc. | Non-adhesive elastic gelatin matrices |
-
2008
- 2008-03-28 HR HRP20160743TT patent/HRP20160743T1/hr unknown
- 2008-03-28 IE IE20080229A patent/IES20080229A2/en not_active IP Right Cessation
- 2008-03-28 EP EP08719893.3A patent/EP2139457B1/en active Active
- 2008-03-28 EP EP16154811.0A patent/EP3085363B1/en active Active
- 2008-03-28 PL PL16154811T patent/PL3085363T3/pl unknown
- 2008-03-28 HU HUE16154811A patent/HUE043185T2/hu unknown
- 2008-03-28 DK DK08719893.3T patent/DK2139457T3/da active
- 2008-03-28 LT LTEP16154811.0T patent/LT3085363T/lt unknown
- 2008-03-28 PT PT16154811T patent/PT3085363T/pt unknown
- 2008-03-28 DK DK16154811.0T patent/DK3085363T3/da active
- 2008-03-28 HU HUE08719893A patent/HUE027803T2/en unknown
- 2008-03-28 WO PCT/IE2008/000035 patent/WO2008117268A2/en not_active Ceased
- 2008-03-28 SI SI200831641A patent/SI2139457T1/sl unknown
- 2008-03-28 ES ES16154811T patent/ES2718542T3/es active Active
- 2008-03-28 DE DE202008018583.1U patent/DE202008018583U1/de not_active Expired - Lifetime
- 2008-03-28 ES ES08719893.3T patent/ES2582368T3/es active Active
- 2008-03-28 TR TR2019/05174T patent/TR201905174T4/tr unknown
- 2008-03-28 PT PT87198933T patent/PT2139457T/pt unknown
- 2008-03-28 JP JP2010500426A patent/JP5372905B2/ja not_active Expired - Fee Related
- 2008-03-28 PL PL08719893.3T patent/PL2139457T3/pl unknown
- 2008-03-28 SI SI200832058T patent/SI3085363T1/sl unknown
-
2016
- 2016-07-14 CY CY20161100677T patent/CY1117814T1/el unknown
-
2019
- 2019-04-12 CY CY20191100409T patent/CY1121568T1/el unknown
- 2019-04-15 HR HRP20190699TT patent/HRP20190699T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IES20080229A2 (en) | 2008-12-24 |
| SI2139457T1 (sl) | 2016-09-30 |
| ES2718542T3 (es) | 2019-07-02 |
| LT3085363T (lt) | 2019-06-25 |
| HUE027803T2 (en) | 2016-10-28 |
| EP3085363B1 (en) | 2019-03-20 |
| PT3085363T (pt) | 2019-05-16 |
| PL2139457T3 (pl) | 2016-11-30 |
| ES2582368T3 (es) | 2016-09-12 |
| EP3085363A1 (en) | 2016-10-26 |
| TR201905174T4 (tr) | 2019-05-21 |
| PL3085363T3 (pl) | 2019-08-30 |
| EP2139457B1 (en) | 2016-05-04 |
| HUE043185T2 (hu) | 2019-08-28 |
| CY1121568T1 (el) | 2020-05-29 |
| EP2139457A2 (en) | 2010-01-06 |
| JP5372905B2 (ja) | 2013-12-18 |
| WO2008117268A2 (en) | 2008-10-02 |
| DE202008018583U1 (de) | 2016-03-14 |
| WO2008117268A3 (en) | 2009-03-26 |
| HRP20190699T1 (hr) | 2019-07-12 |
| PT2139457T (pt) | 2016-07-26 |
| JP2010522738A (ja) | 2010-07-08 |
| DK2139457T3 (da) | 2016-07-25 |
| HRP20160743T1 (hr) | 2016-09-23 |
| CY1117814T1 (el) | 2017-05-17 |
| SI3085363T1 (sl) | 2019-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2139457T3 (da) | Lægemiddelafgivelsesindretning til at tilvejebringe lokal analgesi, lokal anæstesi eller nerveblokade | |
| US8034368B2 (en) | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage | |
| EP1809329B1 (en) | Sustained local anesthetic composition containing saib | |
| CN103140226B (zh) | 用于治疗脊髓损伤的制剂 | |
| JP2004521111A (ja) | 局所麻酔薬および使用法 | |
| CA2294950C (en) | Levobupivacaine and its use | |
| USRE47826E1 (en) | Drug delivery device for providing local analgesia, local anesthesia or nerve blockage | |
| US20080241243A1 (en) | Drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
| CN111629713B (zh) | 用于治疗手术后疼痛的药物组合物 | |
| HK1230090B (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
| HK1230090A1 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
| IE20080229U1 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
| IES85185Y1 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
| IE85880B1 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
| IE20070220A1 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
| WO2022219179A1 (en) | Drug-release implant for soft tissue surgery | |
| HK40035093B (zh) | 用於治疗手术後疼痛的药物组合物 | |
| WO2021232157A1 (en) | Sustained release pharmaceutical composition | |
| HK40035093A (en) | Pharmaceutical compositions for the treatment of postoperative pain | |
| HK1201437B (en) | Sustained local anesthetic composition containing saib | |
| MXPA00000397A (es) | Levobupivacaina y su uso | |
| Stief | 326: Improvement in Pharmacokinetic Characteristics of Perfalgan® After an Infusion Over 60 Minutes, in a Porcine Model |